Northwest Biotherapeutics (NWBO) Other financing activities (2010 - 2026)

Northwest Biotherapeutics' Other financing activities history runs 16 years deep, the most recent figure standing at $6000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 64.71% year-over-year to $6000.0 in Q1 2026; TTM through Mar 2026 was $12000.0, a 95.02% decrease from a year earlier, with the FY2025 full-year figure at $23000.0, down 98.5% from the prior year.
• Other financing activities held at $6000.0 in Q1 2026 per NWBO's latest filing, from $6000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $5.4 million in Q2 2022 and bottomed at $6000.0 in Q2 2025.
• The 5-year median for Other financing activities is $180000.0 (2024), against an average of $958733.3.
• Across the five-year window, Other financing activities surged 461.74% in 2022 and plunged 98.7% in 2025, its largest moves.
• Year by year, Other financing activities stood at $1.1 million in 2022, then plunged by 89.32% to $119000.0 in 2023, then tumbled by 84.87% to $18000.0 in 2024, then sank by 66.67% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
• Per Business Quant, the three latest NWBO Other financing activities figures stand at $6000.0 (Q1 2026), $6000.0 (Q2 2025), and $17000.0 (Q1 2025).